Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

4.230 USD -0.030 (-0.70%)
Official Closing Price Updated: 7:57 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Xeris Pharmaceuticals Inc

< Previous 1 2 3 Next >
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
NASDAQ:XERS Shareholder Notice: Investigation over Possible Securities Laws Violations by Xeris Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 03/22/2021 -- Xeris Pharmaceuticals, Inc. is under investigation concerning potential violations of securities laws in connection with certain financial statements. 
From SBWire - Latest Press Releases
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS
Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS
Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Thinking about buying stock in Artelo Biosciences, Xeris Pharmaceuticals, Inovio Pharmaceuticals, Novan, or Fisker?
InvestorsObserver issues critical PriceWatch Alerts for ARTL, XERS, INO, NOVN, and FSR. 
From PR Newswire
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Dia
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors
ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of... 
From Business Wire News Releases
Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO. 
From PR Newswire
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Ye
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and... 
From Business Wire News Releases
Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Thinking about buying stock in Under Armour, Cassava Sciences, Norwegian Cruise Line, Xeris Pharmaceuticals, or Delta Air Lines?
InvestorsObserver issues critical PriceWatch Alerts for UAA, SAVA, NCLH, XERS, and DAL. 
From PR Newswire
Thinking about buying stock in Marinus Pharmaceuticals, Fiat Chrysler, Lithium Americas, Xeris Pharmaceuticals, or Nokia?
InvestorsObserver issues critical PriceWatch Alerts for MRNS, FCAU, LAC, XERS, and NOK. 
From PR Newswire
Thinking about buying stock in Rockwell Medical, Spotify, Xeris Pharmaceuticals, Blink Charging, or Nio Inc?
InvestorsObserver issues critical PriceWatch Alerts for RMTI, SPOT, XERS, BLNK, and NIO. 
From PR Newswire
Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug... 
From Business Wire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.